Elenco degli articoli con argomento «dermatite atopica»
Dermatologia24 nov 2023
Un aggiornamento per te da Eadv 2023
Inibitori di JAK nelle indicazioni dermatologiche
25 ott 2023
Risk of Inflammatory Bowel
Data on the association between atopic dermatitis (AD) and inflammatory bowel disease
10 ott 2023
Impact of Baricitinib on Patients'
The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials
29 set 2023
Efficacy and safeness of tralokinumab in patients with atopic dermatitis
Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: A case series
14 set 2023
Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis
Atopic dermatitis (AD), a relapsing, inflammatory skin disease, is associated with pruritus that can negatively affect patients’ quality of life
31 ago 2023
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib
Characterization of upadacitinib use and switching from dupilumab to upadacitinib among patients with moderate-to-severe atopic dermatitis (AD) is needed.
01 ago 2023
Lebrikizumab for the Treatment
Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder
17 lug 2023
The differential effects of upadacitinib treatment on skin
Upadacitinib is an oral Janus kinase (JAK) 1 inhibitor approved in Japan for moderate-to-severe atopic dermatitis
03 lug 2023
Abrocitinib efficacy and safety in patients
Abrocitinib improved signs and symptoms of moderate-to-severe atopic dermatitis (AD) at 12/16 weeks in phase 3 studies with a manageable safety profile
05 giu 2023
Definition of the Clinical Characteristics of Patients with Moderate and Severe Atopic Dermatitis
Narrow-band (NB) UVB and UVA1 have been successfully used for the treatment of atopic dermatitis (AD) since the 1980s
04 mag 2023
Open day con consulti gratuiti in Abruzzo dalla parte della tua pelle
La Campagna nazionale di sensibilizzazione sulla Dermatite Atopica promossa dai dermatologi SIDeMaST torna a Chieti e a l’Aquila.
04 mag 2023
Efficacy and safety of abrocitinib monotherapy in adolescents and adults
Differences in atopic dermatitis (AD) disease course and manifestation with age may extend to treatment response
17 apr 2023
In Lombardia open day sulla dermatite atopica
Consulti gratuiti l'11 e il 18 marzo a Milano e Brescia
12 apr 2023
Al policlinico Federico II open day sulla dermatite atopica
Sabato 11 marzo al policlinico Federico II
31 mar 2023
Open day dermatite atopica in tutta Italia
L’11, 18 e 25 MARZO 2023 torna “Dalla parte della tua pelle”, la campagna Nazionale di sensibilizzazione sulla Dermatite Atopica dell’adulto.
14 mar 2023
Campagna nazionale di sensibilizzazione sulla Dermatite Atopica
Torna la Campagna nazionale di sensibilizzazione sulla Dermatite Atopica. L'11, il 18 e il 25 marzo consulti gratuiti.
20 feb 2023
A Review on the Safety of Using JAK Inhibitors in Dermatology
Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions
20 feb 2023
Treatment of Severe Atopic Dermatitis with Dupilumab
Atopic dermatitis is a chronic inflammatory intensively pruritic skin disease.
17 feb 2023
Dalla parte della tua pelle
Prevenzione e cura della dermatite atopica: torna la campagna nazionale di sensibilizzazione sulla dermatite atopica dell’adulto edizione 2023
30 gen 2023
Prevalence of and association between atopic dermatitis
Atopic dermatitis (AD) and food allergy (FA) share similar type 2 inflammation and commonly co-occur